» Articles » PMID: 28567503

Planning Benchmark Study for SBRT of Early Stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy

Abstract

Purpose: The aim was to evaluate stereotactic body radiation therapy (SBRT) treatment planning variability for early stage nonsmall cell lung cancer (NSCLC) with respect to the published guidelines of the Stereotactic Radiotherapy Working Group of the German Society for Radiation Oncology (DEGRO).

Materials And Methods: Planning computed tomography (CT) scan and the structure sets (planning target volume, PTV; organs at risk, OARs) of 3 patients with early stage NSCLC were sent to 22 radiotherapy departments with SBRT experience: each department was asked to prepare a treatment plan according to the DEGRO guidelines. The prescription dose was 3 fractions of 15 Gy to the 65% isodose.

Results: In all, 87 plans were generated: 36 used intensity-modulated arc therapy (IMAT), 21 used three-dimensional conformal radiation therapy (3DCRT), 6 used static field intensity-modulated radiation therapy (SF-IMRT), 9 used helical radiotherapy and 15 used robotic radiosurgery. PTV dose coverage and simultaneously kept OARs doses were within the clinical limits published in the DEGRO guidelines. However, mean PTV dose (mean 58.0 Gy, range 52.8-66.4 Gy) and dose conformity indices (mean 0.75, range 0.60-1.00) varied between institutions and techniques (p ≤ 0.02). OARs doses varied substantially between institutions, but appeared to be technique independent (p = 0.21).

Conclusion: All studied treatment techniques are well suited for SBRT of early stage NSCLC according to the DEGRO guidelines. Homogenization of SBRT practice in Germany is possible through the guidelines; however, detailed treatment plan characteristics varied between techniques and institutions and further homogenization is warranted in future studies and recommendations. Optimized treatment planning should always follow the ALARA (as low as reasonably achievable) principle.

Citing Articles

Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery.

Brunner T, Boda-Heggemann J, Burgy D, Corradini S, Dieckmann U, Gawish A Strahlenther Onkol. 2024; 200(9):737-750.

PMID: 38997440 PMC: 11343978. DOI: 10.1007/s00066-024-02254-2.


Noninvasive cardiac radioablation for ventricular tachycardia: dosimetric comparison between linear accelerator- and robotic CyberKnife-based radiosurgery systems.

Wang C, Ho L, Lin L, Chan H, Chen H, Yu T Radiat Oncol. 2023; 18(1):187.

PMID: 37950307 PMC: 10638803. DOI: 10.1186/s13014-023-02370-w.


Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities.

Gkika E, Kostyszyn D, Fechter T, Moustakis C, Ernst F, Boda-Heggemann J Strahlenther Onkol. 2023; 199(11):973-981.

PMID: 37268767 PMC: 10598103. DOI: 10.1007/s00066-023-02085-7.


The role of EPID in vivo dosimetry in the risk management of stereotactic lung treatments.

Esposito M, Mancosu P, Bruschi A, Ghirelli A, Pini S, Alpi P Strahlenther Onkol. 2023; 199(11):992-999.

PMID: 37256302 DOI: 10.1007/s00066-023-02081-x.


Dose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study.

Das I, Yadav P, Andersen A, Chen Z, Huang L, Langer M Radiother Oncol. 2023; 182:109571.

PMID: 36822361 PMC: 10121952. DOI: 10.1016/j.radonc.2023.109571.


References
1.
Chan M, Kwong D, Law G, Tam E, Tong A, Lee V . Dosimetric evaluation of four-dimensional dose distributions of CyberKnife and volumetric-modulated arc radiotherapy in stereotactic body lung radiotherapy. J Appl Clin Med Phys. 2013; 14(4):4229. PMC: 5714543. DOI: 10.1120/jacmp.v14i4.4229. View

2.
Maquilan G, Timmerman R . Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer. Cancer J. 2016; 22(4):274-9. DOI: 10.1097/PPO.0000000000000204. View

3.
Grimm J, LaCouture T, Croce R, Yeo I, Zhu Y, Xue J . Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys. 2011; 12(2):3368. PMC: 5718687. DOI: 10.1120/jacmp.v12i2.3368. View

4.
vant Riet A, Mak A, Moerland M, Elders L, Van Der Zee W . A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. Int J Radiat Oncol Biol Phys. 1997; 37(3):731-6. DOI: 10.1016/s0360-3016(96)00601-3. View

5.
Chang J, Senan S, Paul M, Mehran R, Louie A, Balter P . Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16(6):630-7. PMC: 4489408. DOI: 10.1016/S1470-2045(15)70168-3. View